Ping Xu1, Jeffrey P Krischer2. 1. Health Informatics Institute, College of Medicine, University of South Florida, Tampa, FL xup@epi.usf.edu. 2. Health Informatics Institute, College of Medicine, University of South Florida, Tampa, FL.
Abstract
OBJECTIVE: To define prognostic classification factors associated with the progression from single to multiple autoantibodies, multiple autoantibodies to dysglycemia, and dysglycemia to type 1 diabetes onset in relatives of individuals with type 1 diabetes. RESEARCH DESIGN AND METHODS: Three distinct cohorts of subjects from the Type 1 Diabetes TrialNet Pathway to Prevention Study were investigated separately. A recursive partitioning analysis (RPA) was used to determine the risk classes. Clinical characteristics, including genotype, antibody titers, and metabolic markers were analyzed. RESULTS: Age and GAD65 autoantibody (GAD65Ab) titers defined three risk classes for progression from single to multiple autoantibodies. The 5-year risk was 11% for those subjects >16 years of age with low GAD65Ab titers, 29% for those ≤16 years of age with low GAD65Ab titers, and 45% for those subjects with high GAD65Ab titers regardless of age. Progression to dysglycemia was associated with islet antigen 2 Ab titers, and 2-h glucose and fasting C-peptide levels. The 5-year risk is 28%, 39%, and 51% for respective risk classes defined by the three predictors. Progression to type 1 diabetes was associated with the number of positive autoantibodies, peak C-peptide level, HbA1c level, and age. Four risk classes defined by RPA had a 5-year risk of 9%, 33%, 62%, and 80%, respectively. CONCLUSIONS: The use of RPA offered a new classification approach that could predict the timing of transitions from one preclinical stage to the next in the development of type 1 diabetes. Using these RPA classes, new prevention techniques can be tailored based on the individual prognostic risk characteristics at different preclinical stages.
OBJECTIVE: To define prognostic classification factors associated with the progression from single to multiple autoantibodies, multiple autoantibodies to dysglycemia, and dysglycemia to type 1 diabetes onset in relatives of individuals with type 1 diabetes. RESEARCH DESIGN AND METHODS: Three distinct cohorts of subjects from the Type 1 Diabetes TrialNet Pathway to Prevention Study were investigated separately. A recursive partitioning analysis (RPA) was used to determine the risk classes. Clinical characteristics, including genotype, antibody titers, and metabolic markers were analyzed. RESULTS: Age and GAD65 autoantibody (GAD65Ab) titers defined three risk classes for progression from single to multiple autoantibodies. The 5-year risk was 11% for those subjects >16 years of age with low GAD65Ab titers, 29% for those ≤16 years of age with low GAD65Ab titers, and 45% for those subjects with high GAD65Ab titers regardless of age. Progression to dysglycemia was associated with islet antigen 2 Ab titers, and 2-h glucose and fasting C-peptide levels. The 5-year risk is 28%, 39%, and 51% for respective risk classes defined by the three predictors. Progression to type 1 diabetes was associated with the number of positive autoantibodies, peak C-peptide level, HbA1c level, and age. Four risk classes defined by RPA had a 5-year risk of 9%, 33%, 62%, and 80%, respectively. CONCLUSIONS: The use of RPA offered a new classification approach that could predict the timing of transitions from one preclinical stage to the next in the development of type 1 diabetes. Using these RPA classes, new prevention techniques can be tailored based on the individual prognostic risk characteristics at different preclinical stages.
Authors: Jeffrey P Krischer; Kristian F Lynch; Desmond A Schatz; Jorma Ilonen; Åke Lernmark; William A Hagopian; Marian J Rewers; Jin-Xiong She; Olli G Simell; Jorma Toppari; Anette-G Ziegler; Beena Akolkar; Ezio Bonifacio Journal: Diabetologia Date: 2015-02-10 Impact factor: 10.122
Authors: Jeffrey L Mahon; Jay M Sosenko; Lisa Rafkin-Mervis; Heidi Krause-Steinrauf; John M Lachin; Clinton Thompson; Polly J Bingley; Ezio Bonifacio; Jerry P Palmer; George S Eisenbarth; Joseph Wolfsdorf; Jay S Skyler Journal: Pediatr Diabetes Date: 2008-09-24 Impact factor: 4.866
Authors: V Parikka; K Näntö-Salonen; M Saarinen; T Simell; J Ilonen; H Hyöty; R Veijola; M Knip; O Simell Journal: Diabetologia Date: 2012-03-23 Impact factor: 10.122
Authors: Ezio Bonifacio; Liping Yu; Alastair K Williams; George S Eisenbarth; Polly J Bingley; Santica M Marcovina; Kerstin Adler; Anette G Ziegler; Patricia W Mueller; Desmond A Schatz; Jeffrey P Krischer; Michael W Steffes; Beena Akolkar Journal: J Clin Endocrinol Metab Date: 2010-05-05 Impact factor: 5.958
Authors: Ping Xu; Craig A Beam; David Cuthbertson; Jay M Sosenko; Jay S Skyler; Jeffrey P Krischer Journal: Diabetes Care Date: 2012-07-11 Impact factor: 19.112
Authors: Jay M Sosenko; Jay S Skyler; Jerry P Palmer; Jeffrey P Krischer; David Cuthbertson; Liping Yu; Desmond A Schatz; Tihamer Orban; George Eisenbarth Journal: Diabetes Care Date: 2011-09-12 Impact factor: 19.112
Authors: Tihamer Orban; Jay M Sosenko; David Cuthbertson; Jeffrey P Krischer; Jay S Skyler; Richard Jackson; Liping Yu; Jerry P Palmer; Desmond Schatz; George Eisenbarth Journal: Diabetes Care Date: 2009-09-09 Impact factor: 17.152
Authors: Emanuele Bosi; David C Boulware; Dorothy J Becker; Jane H Buckner; Susan Geyer; Peter A Gottlieb; Courtney Henderson; Amanda Kinderman; Jay M Sosenko; Andrea K Steck; Polly J Bingley Journal: J Clin Endocrinol Metab Date: 2017-08-01 Impact factor: 5.958
Authors: Christine Ferrara-Cook; Susan Michelle Geyer; Carmella Evans-Molina; Ingrid M Libman; Dorothy J Becker; Stephen E Gitelman; Maria Jose Redondo Journal: Diabetes Care Date: 2020-01-14 Impact factor: 19.112
Authors: Christine T Ferrara; Susan M Geyer; Carmella Evans-Molina; Ingrid M Libman; Dorothy J Becker; John M Wentworth; Antoinette Moran; Stephen E Gitelman; Maria J Redondo Journal: J Clin Endocrinol Metab Date: 2017-12-01 Impact factor: 5.958
Authors: Stephen R Karpen; Jessica L Dunne; Brigitte I Frohnert; Marjana Marinac; Claudia Richard; Sarah E David; Inish M O'Doherty Journal: Diabetologia Date: 2022-07-22 Impact factor: 10.460
Authors: Andrea K Steck; Fran Dong; Brigitte I Frohnert; Kathleen Waugh; Michelle Hoffman; Jill M Norris; Marian J Rewers Journal: J Autoimmun Date: 2018-02-01 Impact factor: 7.094
Authors: Polly J Bingley; Diane K Wherrett; Ann Shultz; Lisa E Rafkin; Mark A Atkinson; Carla J Greenbaum Journal: Diabetes Care Date: 2018-04 Impact factor: 19.112
Authors: Maria J Redondo; Andrea K Steck; Jay Sosenko; Mark Anderson; Peter Antinozzi; Aaron Michels; John M Wentworth; Mark A Atkinson; Alberto Pugliese; Susan Geyer Journal: Diabetes Care Date: 2018-10-01 Impact factor: 19.112
Authors: Carla J Greenbaum; Cate Speake; Jeffrey Krischer; Jane Buckner; Peter A Gottlieb; Desmond A Schatz; Kevan C Herold; Mark A Atkinson Journal: Diabetes Date: 2018-05-16 Impact factor: 9.461
Authors: Mustafa Tosur; Susan M Geyer; Henry Rodriguez; Ingrid Libman; David A Baidal; Maria J Redondo Journal: Diabetologia Date: 2018-06-21 Impact factor: 10.122